ACTRN12623000211662
Completed
Phase 2
A Biomarker-Driven Approach to Identify Pathogenic Mechanisms and Novel Therapeutic Targets in Chronic Wounds (Pyoderma Gangrenosum) using Tildrakizumab
iverpool Hospital0 sites10 target enrollmentFebruary 28, 2023
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- iverpool Hospital
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age greater than or equal to 18 years
- •A minimum of one (1\) active ulcer of Pyoderma Gangrenosum as determined by the PI
Exclusion Criteria
- •Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
- •Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic immunosuppressants (those with prior use of these medications must have conducted a washout period of 4 weeks or 5 half\-lives of the drug, whichever is longer).
- •Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well\-being of the participant during any study procedures or the integrity of the data.
- •Have received a vaccination with a live viral of bacterial component within 4 weeks or less of intended Tildrakizumab administration
- •Patients not willing to abstain from receiving live vaccinations during treatment and for at least 17 weeks after treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Identification and analysis of biomarkers for the course of demyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosisDemyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosisDRKS00031139MPI-NAT1,000
Recruiting
Not Applicable
Discovery of Novel Biomarkers for the Diagnosis of TB DiseaseA15Respiratory tuberculosis, bacteriologically and histologically confirmedDRKS00032445Roche360
Recruiting
Not Applicable
Testing novel biomarkers for the diagnosis of the delayed sleep wake phase disorder (DSWPD) in young adultsG47Sleep disordersDRKS00030981Charitè Universitätmedizin (Chronobiology Lab)32
Not yet recruiting
Not Applicable
Identification of biomarkers and pathogenesis of lung cancer without targeted metabolomics based on uplc-q-tof /MSung cancerITMCTR1900002555The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Recruiting
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)Coronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecifiedDRKS00022871CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover400